Skip to main content
. 2022 Nov 15;132(22):e154229. doi: 10.1172/JCI154229

Figure 12. H3.3-G34R pHGG shows an improved therapeutic response to DDRi in combination with RT, and long-term survivors acquire antitumor immunological memory.

Figure 12

(A) Illustration depicting the time frame of the combined treatment with DDRi and RT. (B) Kaplan-Meier survival plot of H3.3-G34R–bearing mice treated with RT alone or in combination with the PARPi pamiparib. (C) Kaplan-Meier survival plot of H3.3-G34R–bearing mice treated with RT alone or in combination with the CHK1/2i AZD7762. (D) Results of the in vivo imaging of tumor size in response to the DDRi plus RT treatment. The mark indicates that the animal was euthanized because of signs of tumor burden. (E) Kaplan-Meier survival plot of H3.3-G34R–bearing mice that survived following RT plus DDRi therapies and that were rechallenged with H3.3-G34R pHGG cells, compared with naive mice implanted with the same cells (control group). (F) Kaplan-Meier survival plot of CD8-KO mice implanted with H3.3-G34R cells and treated with RT alone or in combination with the CHK1/2i AZD7762 or the PARPi pamiparib. n = 5 mice/group. *P < 0.05, **P < 0.01, and ***P < 0.005; log-rank (Mantel-Cox) test.